Although MS-275 could mobilize other lymphocytes with antitumor potential, selective depletion of CD4 or NK1.1-expressing cells during ACT+MS-275 treatment provided no loss of sustained tumor regression compared with CD8 depletion (Figure 1G). This evidence concerns the gene CD4 and neoplasm.